GC Biopharma will distribute and sell CSL Seqirus’s quadrivalent flu vaccine, ‘Fluad Quad Prefilled Syringe (Fluad Quad),’ in Korea.

According to industry sources on the 3rd, GC Biopharma recently signed a contract with Meditip to distribute and sell Fluad Quad in Korea.

Meditip holds the domestic rights to the main product of the Australian pharmaceutical company CSL Seqirus. It has domestic licenses for the quadrivalent influenza vaccine Fluad Quad and another cell-based quadrivalent influenza vaccine, Flucelvax Quad. 

GC Biopharma already owns its own quadrivalent influenza vaccine, GC Flu. With the addition of Fluad Quad from Seqirus, the company is expected t